ArticleArtificial organs2026
Device-Induced Blood Damage in Pump-Assisted Circulation: A Comparative Study of HeartMate III and BrioVAD Pumps.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMechanical circulatory support (MCS) has emerged as a life-saving intervention and may be a potential alternative to organ transplant for patients with end-stage heart failure. The Heartmate III (HM3) left ventricular assist device (LVAD) is a magnetically levitated centrifugal pump and the most advanced LVAD on the current MCS market. The BrioVAD is a newly developed LVAD featuring a fully magnetically suspended blood pump and has recently been approved by the FDA for the INNOVATE trial in the US. However, device-related complications, which are highly related to blood damage by the pump, remain a major concern for patients with MCS. This study aimed to compare device-induced blood damage by the HM3 and BrioVAD pumps in vitro in a circulatory loop.
methodsThe device-assisted circulatory loop was filled with fresh, healthy human blood. Both pumps were operated under the same clinically relevant condition, i.e., a blood flow rate of 4.5 L/min and an afterload pressure head of 75 mmHg, for 4 h. Hourly blood samples were collected to assess device-induced damage to blood components, including red blood cells, platelets, neutrophils, and von Willebrand factor (VWF).
resultsBoth pumps had comparable impacts on blood components, with no statistically significant difference between them in all the measured parameters (except one neutrophil activation marker). After the four hours of device-assisted circulation, both pumps caused minimal hemolysis and moderate platelet damage but had significant impacts on VWF and neutrophils.
conclusionsThis study provides a comprehensive comparative in vitro analysis of blood damage caused by the HM3 and BrioVAD pumps under a clinically relevant condition. The results provide valuable insight into the potential implications for clinical use of the two devices and guidance for the design of new LVADs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.